Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12405257 | 0.84 | PARP1 (0.65) | ALDH1A1KDM4EPKML3MBTL1PARP1 | |
| SCHEMBL7269288 | 0.83 | MAPT (0.57) | ALDH1A1KDM4ESMN1; SMN2MAPTNPSR1 | |
| SCHEMBL3087984 | 0.81 | PARP1 (0.64) | ALDH1A1KDM4EPKML3MBTL1PARP1 | |
| SCHEMBL7269722 | 0.79 | PARP1 (0.60) | ALDH1A1KDM4EPKML3MBTL1PARP1 | |
| SCHEMBL7276275 | 0.78 | PARP1 (0.56) | ALDH1A1PARP1SMN1; SMN2MAPTMMP12 | |
| SCHEMBL14078801 | 0.78 | PARP1 (0.56) | ALDH1A1KDM4EPARP1SMN1; SMN2MAPT | |
| SCHEMBL10923540 | 0.77 | PARP1 (0.69) | ALDH1A1KDM4EPKMPARP1MAPT | |
| SCHEMBL4286655 | 0.76 | PARP1 (0.67) | ALDH1A1KDM4EPKMPARP1MAPT | |
| SCHEMBL32667442 | 0.75 | PARP1 (0.47) | ALDH1A1L3MBTL1PARP1SMN1; SMN2 | |
| SCHEMBL16421393 | 0.75 | PARP1 (0.65) | ALDH1A1KDM4EPKMPARP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | disclosed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-0411751-A1 | Renin inhibitory peptides | Beecham Group p.l.c. (GB) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | ALDH1A1 3130/4885KDM4E 4040/4885PKM 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.